MedTrace Logo

Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure

NCT07177183 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2026-02-05

No results posted yet for this study

Summary

The main objective of the study is to determine whether a subnormal serum creatinine value upon admission to the Post-ICU Care Unit predicts the need for prolonged ventilatory support. A parallel objective of the study is to determine whether exogenous in-take of the dietary supplement creatine in patients with subnormal serum creatinine value is associated with a shortened duration of ventilatory support and improved patients outcome.

Conditions

  • Prolonged Mechanical Ventilation
  • Critical Illness

Interventions

DIETARY_SUPPLEMENT

Dietary supplement creatine

Dietary supplement creatine. The dosage of creatine will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.

DIETARY_SUPPLEMENT

Dietary supplement - placebo

Dietary supplement polydextrose as a placebo. The dosage of placebo will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.

OTHER

No intervention

Patients in Group 1 will serve as controls and will receive no intervention, only standard care.

Sponsors & Collaborators

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Roman Kula, MD, CSc · University Hospital Ostrava

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2027-12-31
Completion
2028-02-02

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07177183 on ClinicalTrials.gov